Pharmacological Management of Coagulation

Correct Answer

B — Aspirin

Rationale

Aspirin is classified as an irreversible inhibitor of cyclooxygenase-1. It acetylates a serine residue in the cyclooxygenase-1 active site, permanently inactivating the enzyme for the platelet lifetime of eight to ten days. Clopidogrel is a P2Y12 receptor antagonist. Ticagrelor is also a P2Y12 receptor antagonist. Abciximab is a glycoprotein IIb/IIIa antagonist.

Correct Answer

A — Clopidogrel

Rationale

Clopidogrel is classified as a P2Y12 receptor antagonist, a class of antiplatelet agents that block the adenosine diphosphate receptor on platelets. Aspirin is a cyclooxygenase-1 inhibitor. Abciximab is a glycoprotein IIb/IIIa antagonist. Warfarin is a vitamin K antagonist anticoagulant.

Correct Answer

C — Abciximab

Rationale

Abciximab is classified as a glycoprotein IIb/IIIa antagonist. Glycoprotein IIb/IIIa is the primary platelet aggregation receptor, and abciximab belongs to the drug class that blocks this receptor, along with eptifibatide and tirofiban. Clopidogrel is a P2Y12 receptor antagonist. Aspirin is a cyclooxygenase-1 inhibitor. Fondaparinux is a selective factor Xa inhibitor and anticoagulant.

Correct Answer

D — Fondaparinux

Rationale

Fondaparinux is a synthetic pentasaccharide classified as a selective factor Xa inhibitor. It accelerates antithrombin III inhibition of factor Xa exclusively, with no direct anti-thrombin activity — distinguishing it from unfractionated heparin and low-molecular-weight heparins, which inhibit both factor Xa and thrombin to varying degrees. Dabigatran is an oral direct thrombin inhibitor. Rivaroxaban is a direct factor Xa inhibitor that does not require antithrombin III.

Correct Answer

A — Dabigatran

Rationale

Dabigatran is the only oral direct thrombin inhibitor currently in clinical use. It is administered as a prodrug (dabigatran etexilate) and directly inhibits thrombin without requiring antithrombin III. Rivaroxaban and apixaban are oral direct factor Xa inhibitors, not thrombin inhibitors. Warfarin is a vitamin K antagonist that reduces synthesis of multiple coagulation factors.

Correct Answer

C — Warfarin

Rationale

Warfarin is classified as a vitamin K antagonist. It inhibits vitamin K epoxide reductase complex subunit 1, reducing the synthesis of functional vitamin K-dependent coagulation factors. Rivaroxaban is a direct factor Xa inhibitor. Dabigatran is a direct thrombin inhibitor. Fondaparinux is a selective factor Xa inhibitor that acts through antithrombin III.

Correct Answer

B — Platelets lack a nucleus and cannot synthesize new cyclooxygenase-1 to replace the acetylated enzyme

Rationale

Aspirin covalently acetylates a serine residue in the active site of cyclooxygenase-1, permanently inactivating the enzyme. Because mature platelets are anucleate, they cannot transcribe or translate new cyclooxygenase-1 to replace the inactivated enzyme. The antiplatelet effect therefore persists for the entire platelet lifespan of eight to ten days, regardless of aspirin's short plasma half-life of fifteen to twenty minutes. This explains why aspirin must be stopped approximately seven to ten days before elective surgery to allow sufficient new platelet production to restore normal hemostasis.

Correct Answer

C — Blockade of P2Y12 prevents ADP from amplifying platelet activation, reducing sustained aggregation at the site of vascular injury

Rationale

ADP released from platelet dense granules binds the P2Y12 receptor on adjacent platelets and amplifies the initial activation signal, sustaining and propagating platelet aggregation at the injury site. P2Y12 antagonists such as clopidogrel, prasugrel, ticagrelor, and cangrelor block this ADP-mediated amplification step, attenuating the hemostatic response without eliminating platelet adhesion or primary activation. The P2Y12 receptor is not involved in collagen recognition, which is mediated by glycoprotein VI. P2Y12 blockade does not inhibit cyclooxygenase-1 or thromboxane A2 synthesis — that is the mechanism of aspirin. P2Y12 signaling does not directly control fibrinogen binding to glycoprotein IIb/IIIa, which requires integrin activation through multiple upstream pathways.

Correct Answer

A — Heparin binds antithrombin III and induces a conformational change that greatly accelerates its inhibition of thrombin and factor Xa

Rationale

Antithrombin III is a serine protease inhibitor that inhibits thrombin, factor Xa, and other coagulation proteases, but does so slowly in the absence of heparin. When heparin binds to a specific pentasaccharide-binding site on antithrombin III, it induces a conformational change that dramatically accelerates the inhibition of thrombin and factor Xa. This is the fundamental mechanism shared by unfractionated heparin, low-molecular-weight heparins, and fondaparinux — all act through antithrombin III rather than directly inhibiting coagulation factors. Heparin does not directly block active sites of thrombin or factor Xa, does not increase antithrombin III synthesis, and does not act through calcium chelation.

Correct Answer

C — Low-molecular-weight heparin chains are too short to simultaneously bridge antithrombin III to thrombin, but long enough to accelerate antithrombin III inhibition of factor Xa

Rationale

Inhibition of thrombin by antithrombin III requires the heparin chain to simultaneously bind both antithrombin III and thrombin, forming a ternary complex. This bridging requires a minimum chain length of approximately 18 saccharide units. Low-molecular-weight heparins have shorter chains that bind and activate antithrombin III but are too short to bridge simultaneously to thrombin. They therefore preferentially accelerate antithrombin III inhibition of factor Xa, which does not require the same ternary complex bridging. Fondaparinux, the shortest heparin analogue (a synthetic pentasaccharide), has no anti-thrombin activity at all for this same reason. The difference is not due to binding affinity, renal clearance rate, or active site binding.

Correct Answer

B — Warfarin prevents synthesis of new vitamin K-dependent clotting factors, but previously synthesized factors must be cleared before anticoagulation is achieved

Rationale

Warfarin inhibits vitamin K epoxide reductase complex subunit 1, the enzyme responsible for recycling vitamin K to its reduced, active form. Without reduced vitamin K, the liver cannot carboxylate the glutamate residues required for functional activity of factors II, VII, IX, X and proteins C and S. However, warfarin does not destroy existing coagulation factors already in circulation — it only prevents new synthesis. The time to therapeutic anticoagulation is therefore determined by the clearance half-lives of the existing vitamin K-dependent factors, with factor VII (the shortest half-life, approximately six hours) falling first and factor II (prothrombin, the longest half-life, approximately sixty to seventy-two hours) falling last. Full anticoagulation typically requires four to five days of warfarin therapy.

Correct Answer

D — Warfarin reduces protein C levels before procoagulant factor levels fall sufficiently, creating a transient procoagulant state that causes dermal vessel thrombosis

Rationale

Protein C is a vitamin K-dependent anticoagulant protein with a shorter half-life than the procoagulant factors II, IX, and X. When warfarin is started, protein C levels fall rapidly while the procoagulant factors remain relatively preserved during the first one to three days. In patients with already-reduced protein C levels due to inherited deficiency, this transient imbalance creates a markedly procoagulant state in the dermal microvasculature, resulting in fibrin thrombi in small vessels, ischemia, and skin necrosis. This is why therapeutic heparin anticoagulation must overlap with warfarin initiation for at least four to five days — heparin provides anticoagulation while the procoagulant factors are still present but falling, bridging the vulnerable transient window.

Correct Answer

A — Alteplase forms a ternary complex with fibrin and plasminogen that concentrates plasminogen activation at the clot surface, whereas streptokinase activates circulating plasminogen systemically

Rationale

In the absence of fibrin, alteplase (recombinant tissue-type plasminogen activator) has low catalytic activity. When alteplase binds fibrin at the clot surface, a ternary complex forms with fibrin-bound plasminogen that dramatically accelerates plasminogen activation. This concentrates fibrinolytic activity at the thrombus, minimizing systemic plasminogen activation and fibrinogen depletion. Streptokinase, by contrast, forms an equimolar complex with circulating plasminogen, converting both clot-bound and systemic plasminogen to plasmin and producing a systemic lytic state. Reteplase and tenecteplase are modified alteplase variants that preserve this fibrin-specificity mechanism. The distinction is not explained by clearance rate, plasminogen activator inhibitor-1 inhibition, or alpha-2 antiplasmin binding.

Correct Answer

C — Tranexamic acid competitively occupies the lysine-binding sites on plasminogen, preventing plasminogen from binding to fibrin and blocking its activation at the clot surface

Rationale

Tranexamic acid is a synthetic lysine analogue. Plasminogen binds fibrin through lysine-binding sites — this fibrin binding is required for efficient plasminogen activation at the clot surface. By competitively occupying these lysine-binding sites, tranexamic acid prevents plasminogen from docking onto fibrin, thereby blocking the fibrin-dependent amplification of plasminogen activation that drives clot dissolution. Epsilon-aminocaproic acid acts by the same mechanism. Tranexamic acid does not directly inhibit plasmin's proteolytic active site, does not stimulate plasminogen activator inhibitor-1 release, and does not affect tissue-type plasminogen activator secretion from endothelial cells.

Correct Answer

B — Inhibition of cyclooxygenase-1 reduces prostaglandin synthesis, impairing the gastric mucosal protective barrier

Rationale

Cyclooxygenase-1 is constitutively expressed in gastric mucosa, where prostaglandins it produces stimulate mucus and bicarbonate secretion, maintain mucosal blood flow, and support epithelial repair. Aspirin irreversibly inhibits cyclooxygenase-1, reducing gastric prostaglandin synthesis and impairing these protective functions. The result is a mucosa vulnerable to acid-peptic injury, producing gastric ulcers and gastrointestinal bleeding. This is the same isoform responsible for platelet thromboxane A2 synthesis — the therapeutic target of aspirin — making gastrointestinal toxicity a predictable on-target adverse effect. Cyclooxygenase-2 inhibition is associated with gastrointestinal protection relative to non-selective agents, not injury.

Correct Answer

A — Direct thrombin inhibitors, because they inhibit thrombin without requiring antithrombin III and are not affected by heparin-induced thrombocytopenia antibodies

Rationale

Heparin-induced thrombocytopenia is caused by IgG antibodies against complexes of heparin and platelet factor 4, which activate platelets and produce a paradoxical prothrombotic state. Both unfractionated heparin and low-molecular-weight heparins are contraindicated because they carry significant cross-reactivity with these antibodies. Direct thrombin inhibitors such as argatroban and bivalirudin are the preferred anticoagulants in this setting: they bind directly to the active site of thrombin independently of antithrombin III, have no interaction with platelet factor 4, and are not implicated in heparin-induced thrombocytopenia. Fondaparinux is a selective factor Xa inhibitor that acts through antithrombin III; it does not inhibit thrombin. While it does not bind platelet factor 4 and has very low cross-reactivity with heparin-induced thrombocytopenia antibodies, it is considered an alternative rather than a first-line agent in this setting. Warfarin must not be started until platelet counts recover and adequate anticoagulation with a direct thrombin inhibitor is established, because early warfarin initiation in heparin-induced thrombocytopenia risks venous limb gangrene through the same protein C depletion mechanism responsible for warfarin-induced skin necrosis.

Correct Answer

B — Fluconazole inhibits CYP2C9, the principal enzyme responsible for warfarin metabolism, increasing warfarin plasma concentrations and anticoagulant effect

Rationale

Warfarin is metabolized predominantly by CYP2C9 in the liver. Fluconazole is a potent inhibitor of CYP2C9 and, to a lesser degree, CYP3A4. When fluconazole is added to a stable warfarin regimen, CYP2C9-mediated warfarin clearance is substantially reduced, causing warfarin plasma concentrations to rise and the INR to increase significantly. This interaction is clinically important and predictable — warfarin dose reduction and more frequent INR monitoring are required whenever azole antifungals are prescribed concurrently. Protein binding displacement is generally a transient and minor contributor to drug interactions. Fluconazole does not induce vitamin K epoxide reductase, and although broad-spectrum antibiotics can reduce gut flora vitamin K production, this is not fluconazole's primary mechanism and would not account for an INR nearly doubling within one week.

Correct Answer

D — Active intracranial hemorrhage is an absolute contraindication to thrombolytic therapy because systemic plasminogen activation would dissolve the fibrin clot that is limiting the bleed

Rationale

Alteplase is a thrombolytic agent that activates plasminogen to plasmin, which dissolves fibrin clots. In a patient with active intracranial hemorrhage, the fibrin clot at the site of bleeding is a critical component of hemostasis. Administration of alteplase would activate plasminogen systemically, dissolving this fibrin plug and converting a contained hemorrhage into catastrophic, uncontrolled bleeding. Active intracranial hemorrhage — including subarachnoid hemorrhage — is therefore an absolute contraindication to thrombolytic therapy regardless of the indication being considered. Other absolute contraindications include recent intracranial surgery, prior hemorrhagic stroke, and uncontrolled hypertension. Age alone does not preclude thrombolytic use, and the other options describe mechanisms or restrictions that are not clinically established.